Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension

Xanthouli, Panagiota; Gordjani, Ojan; Benjamin, Nicola; Harutyunova, Satenik; Egenlauf, Benjamin; Marra, Alberto M.; Haas, Simon; Milde, Nicklas; Blank, Norbert; Lorenz, Hanns-Martin; Fiehn, Christoph; Ulrich, Silvia; Distler, Oliver; Grünig, Ekkehard; Eichstaedt, Christina A.

doi:10.1186/s13075-023-03020-y

Table 1 Characteristics of the patients at baseline

From: Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension

Parameter [unit]	Whole cohort (n = 171)
Parameter [unit]	Mean or n	±	SD or (%)	95%CI	n
Age [years]	60.15	±	13.16	58.16 to 62.13
Height [cm]	165.56	±	8.31	164.30 to 166.81
Weight [kg]	69.84	±	15.62	67.48 to 72.20
Female sex, no. [%]	139		81.3%
World Health Organization functional class
I	34		19.9%
II	85		49.7%
III	46		26.9%
IV	6		3.5%
SSc subgroups
Limited cutaneous SSc	132		77.2%
Diffuse cutaneous SSc	39		22.8%
SSc disease duration [years]	8.31	±	9.38	6.88 to 9.73	168
Modified Rodnan Skin Score	10.99	±	11.01	8.74 to 13.24	94
Oxygen saturation [%]	95.66	±	3.44	95.14 to 96.18
Digital ulcers	65		39.4%		165
Arterial hypertension	67		39.4%		170
Pulmonary fibrosis	73		42.7%
Hemodynamics at rest
mPAP [mmHg]	23.84	±	10.12	22.31 to 25.37
PAWP [mmHg]	10.45	±	4.21	9.82 to 11.09	170
Cardiac output [l/min]	5.29	±	1.58	5.05 to 5.53	167
Cardiac index [l/min/m²]	3.06	±	0.85	2.93 to 3.19	169
PVR [WU]	2.80	±	2.19	2.47 to 3.13	170
Echocardiography at rest
Right atrial area [cm²]	13.45	±	4.80	12.71 to 14.19	164
Right ventricular area [cm²]	15.29	±	4.21	14.64 to 15.94	164
sPAP [mmHg]	35.20	±	14.48	32.97 to 37.43	164
TAPSE [mm]	23.61	±	4.88	22.86 to 24.36	165
Lung function
VCmax [%]	92.03	±	23.74	88.39 to 95.67	166
FEV1 [l]	2.26	±	0.71	2.15 to 2.37	166
TLC [l]	5.03	±	1.21	4.84 to 5.21	166
DLCO [%]	56.88	±	19.71	53.73 to 60.03	153
DLCO/VA [%]	68.25	±	20.83	64.96 to 71.54	156
Laboratory
NTproBNP [ng/l]	584.37	±	1487.97	353.51 to 815.24	162
WBC [/nl]	7.73	±	2.62	7.33 to 8.12
Creatinine [mg/dl]	0.84	±	0.28	0.80 to 0.88
GFR [ml/min/1.73 m²]	86.20	±	27.56	82.03 to 90.37	170
MCH [pg]	29.89	±	2.02	29.59 to 30.20
MCV [fl]	90.00	±	5.31	89.20 to 90.80
CRP [mg/l]	6.04	±	9.08	4.67 to 7.41
Ferritin [ng/ml]	103.66	±	128.38	83.68 to 123.46	161
Hemoglobin [g/dl]	13.37	±	1.40	13.16 to 13.58
Iron [μmol/l]	12.95	±	6.01	12.01 to 13.88	161
Presence of autoantibodies					146
Anti-Scl-70	48		32.9%
CENT	52		35.6%
Others	46		31.5%
6-min walking distance [m]	428.23	±	103.15	411.65 to 444.82	151

mPAP mean pulmonary arterial pressure, PAWP pulmonary arterial wedge pressure, PVR pulmonary vascular resistance, WU Wood units, sPAP systolic pulmonary arterial pressure, TAPSE tricuspid annular plane systolic excursion, VC vital capacity, FEV1 forced expiratory volume in first second, TLC total lung capacity, DLCO diffusion capacity of carbon monoxide, DLCO/VA diffusion capacity of carbon monoxide divided by the alveolar volume, NTproBNP N-terminal pro-brain natriuretic peptide, WBC white blood cells, GFR glomerular filtration rate, MCH mean corpuscular hemoglobin, MCV mean corpuscular volume, CRP C-reactive protein, Anti-Scl-70 anti-topoisomerase I antibodies, CENT anti-centromere antibodies, Others mostly RNA-polymerase I/II/II, antinuclear antibodies (ANA), fibrillarin, Pm/Scl

Back to article page